EHA Library - The official digital education library of European Hematology Association (EHA)

Abstract
Presentation during EHA2022: All Oral presentations will be presented between Friday, June 10 and Sunday, June 12 and will be accessible for on-demand viewing from Monday, June 20 until Monday, August 15, 2022 on the Congress platform.

Abstract: S242

Type: Oral Presentation

Session title: Immune response and infection in hematology - Clinical

Background
After the efficiency of repeated infusion umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in preventing chronic graft versus host disease (GVHD) from 100 days after haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) was proved in the last trial, we design a sequel clinical trial to further explore the early repeated infusion of UC-MSCs in GVHD prophylaxis.

Aims
To evaluate the efficacy of repeated infsion of MSCs in GVHD prophylaxis from D45 after haplo-HSCT.

Methods
128 qualified subjects aged between 18 and 60 with haplo-HSCT in five transplant centers in Mid-West of China were enrolled and randomly assigned equally into the MSCs group and the control group. Patients in the MSCs group received 4 rounds infusion of UC-MSCs (1×106 cells/kg per two weeks from 45 days after transplantation). We investigated the incidence of GVHD and relapse free survival (GRFS), the incidence and severity of aGVHD and cGVHD and the accumulative relapse rate.

Results
 The one-year GRFS in the MSCs group is 65.6% in the MSCs group, which is significantly higher than the control group (43.7%, P= 0.0129). The accumulative incidence of III-IV aGVHD and severe cGVHD of patients in the MSCs group significantly decreased, which is 3.1% and 6.3%, while the control group is 25.6% and 18.8% (P=0.0089 and P=0.0260). The MSCs infusion did not influence the accumulative relapse rate, which is 10.9% in both groups. 

Conclusion
 In this trial, we proved that early repeated infusion of UC-MSCs could effectively improve the GRFS rate for patients after haplo-HSCT by decreasing the incidence and severity of GVHD without increasing the incidences of relapse for these patients.

Keyword(s): Graft-versus-host disease (GVHD), Haploidentical stem cell transplantation, Mesenchymal stem cell

Presentation during EHA2022: All Oral presentations will be presented between Friday, June 10 and Sunday, June 12 and will be accessible for on-demand viewing from Monday, June 20 until Monday, August 15, 2022 on the Congress platform.

Abstract: S242

Type: Oral Presentation

Session title: Immune response and infection in hematology - Clinical

Background
After the efficiency of repeated infusion umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in preventing chronic graft versus host disease (GVHD) from 100 days after haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) was proved in the last trial, we design a sequel clinical trial to further explore the early repeated infusion of UC-MSCs in GVHD prophylaxis.

Aims
To evaluate the efficacy of repeated infsion of MSCs in GVHD prophylaxis from D45 after haplo-HSCT.

Methods
128 qualified subjects aged between 18 and 60 with haplo-HSCT in five transplant centers in Mid-West of China were enrolled and randomly assigned equally into the MSCs group and the control group. Patients in the MSCs group received 4 rounds infusion of UC-MSCs (1×106 cells/kg per two weeks from 45 days after transplantation). We investigated the incidence of GVHD and relapse free survival (GRFS), the incidence and severity of aGVHD and cGVHD and the accumulative relapse rate.

Results
 The one-year GRFS in the MSCs group is 65.6% in the MSCs group, which is significantly higher than the control group (43.7%, P= 0.0129). The accumulative incidence of III-IV aGVHD and severe cGVHD of patients in the MSCs group significantly decreased, which is 3.1% and 6.3%, while the control group is 25.6% and 18.8% (P=0.0089 and P=0.0260). The MSCs infusion did not influence the accumulative relapse rate, which is 10.9% in both groups. 

Conclusion
 In this trial, we proved that early repeated infusion of UC-MSCs could effectively improve the GRFS rate for patients after haplo-HSCT by decreasing the incidence and severity of GVHD without increasing the incidences of relapse for these patients.

Keyword(s): Graft-versus-host disease (GVHD), Haploidentical stem cell transplantation, Mesenchymal stem cell

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies